{"id":"ca3b9729-b7b1-5267-8b8d-89cfe0ee497d","stable_key":"5d8e27d8-6a74-5560-827f-3f90908bbc34:ala-ms-pilot-atrophy","predicate":"reduces_imaging_measure","statement":"The pilot found less annualized brain-volume loss with ALA than placebo, approximately 0.21% versus 0.65%.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"52db7b84-7693-5ded-87b1-5b2ae7963796","mechanism_event_label":"The imaging result favored treatment in this small study.","subject":{"id":"ab091982-3acb-5a87-80fb-85dfe292c1e0","slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"},"object":{"id":"d7e0eaf0-99bb-5ae9-bba2-8d7b4cc31d59","slug":"progressive-ms-brain-atrophy","display_name":"Brain-volume loss in progressive multiple sclerosis","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"52db7b84-7693-5ded-87b1-5b2ae7963796","stable_key":"5d8e27d8-6a74-5560-827f-3f90908bbc34:ala-ms-pilot-atrophy-event","event_type":"observed_intervention","label":"The imaging result favored treatment in this small study.","description":"The pilot found less annualized brain-volume loss with ALA than placebo, approximately 0.21% versus 0.65%.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ab091982-3acb-5a87-80fb-85dfe292c1e0","slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d7e0eaf0-99bb-5ae9-bba2-8d7b4cc31d59","slug":"progressive-ms-brain-atrophy","display_name":"Brain-volume loss in progressive multiple sclerosis","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ala-research/28680916.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d\", \"start_char\": 0, \"end_char\": 1904, \"text_sha256\": \"fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Two-year randomized placebo-controlled progressive-MS pilot","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Oral lipoic acid 1200 mg/day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small imaging-focused trial; brain volume is a surrogate and the walking comparison was not statistically significant.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The imaging result favored treatment in this small study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ala-p28680916] Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. (2017). https://pubmed.ncbi.nlm.nih.gov/28680916/ DOI: 10.1212/nxi.0000000000000374","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"51 randomized participants with secondary progressive multiple sclerosis","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"81ee04b7-5a20-557f-8320-bf20c79801ba","evidence_kind":"source_excerpt","locator":"Lines 1235-1246","start_line":1235,"end_line":1246,"excerpt":"### ala-ms-pilot-atrophy\nThe pilot found less annualized brain-volume loss with ALA than placebo, approximately 0.21% versus 0.65%.\nCondition category: normal\nnutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The imaging result favored treatment in this small study.\norganism: Human\ntissue_or_cell_type: 51 randomized participants with secondary progressive multiple sclerosis\nexperimental_model: Two-year randomized placebo-controlled progressive-MS pilot\nlimitations: Small imaging-focused trial; brain volume is a surrogate and the walking comparison was not statistically significant.\nexposure: Oral lipoic acid 1200 mg/day\nevidence_span: {\"source_cache\": \"artifacts/ala-research/28680916.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d\", \"start_char\": 0, \"end_char\": 1904, \"text_sha256\": \"fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d\"}\n[ala-p28680916] Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. (2017). https://pubmed.ncbi.nlm.nih.gov/28680916/ DOI: 10.1212/nxi.0000000000000374","model_system":"Two-year randomized placebo-controlled progressive-MS pilot","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ala-p28680916] Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. (2017). https://pubmed.ncbi.nlm.nih.gov/28680916/ DOI: 10.1212/nxi.0000000000000374","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d8afa8c2-ced9-5b28-90ca-2ac120ec7202","stable_key":"import-5d8e27d8-6a74-5560-827f-3f90908bbc34","title":"Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"611da198ab85a272eb26b64ee330ef6d1a762853a8481f3191c4acfca9f3cf3d","revision_id":"618b4ce6-3157-5222-8325-408064be5ea5","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}